proton therapy usa limited
proton therapy usa limited Company Information
Company Number
07964052
Website
www.floridaproton.orgRegistered Address
flat 1 55 portland place, london, W1B 1QL
Industry
Manufacture of irradiation, electromedical and electrotherapeutic equipment
Telephone
-
Next Accounts Due
March 2025
Group Structure
View All
Shareholders
emess biosciences ltd 100%
proton therapy usa limited Estimated Valuation
Pomanda estimates the enterprise value of PROTON THERAPY USA LIMITED at £306k based on a Turnover of £412.2k and 0.74x industry multiple (adjusted for size and gross margin).
proton therapy usa limited Estimated Valuation
Pomanda estimates the enterprise value of PROTON THERAPY USA LIMITED at £375.8k based on an EBITDA of £76.5k and a 4.91x industry multiple (adjusted for size and gross margin).
proton therapy usa limited Estimated Valuation
Pomanda estimates the enterprise value of PROTON THERAPY USA LIMITED at £137.3k based on Net Assets of £57.4k and 2.39x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Proton Therapy Usa Limited Overview
Proton Therapy Usa Limited is a live company located in london, W1B 1QL with a Companies House number of 07964052. It operates in the manufacture of irradiation, electromedical and electrotherapeutic equipment sector, SIC Code 26600. Founded in February 2012, it's largest shareholder is emess biosciences ltd with a 100% stake. Proton Therapy Usa Limited is a established, micro sized company, Pomanda has estimated its turnover at £412.2k with unknown growth in recent years.
Upgrade for unlimited company reports & a free credit check
Proton Therapy Usa Limited Health Check
Pomanda's financial health check has awarded Proton Therapy Usa Limited a 3.5 rating. We use a traffic light system to show it exceeds the industry average on 2 measures and has 5 areas for improvement. Company Health Check FAQs
2 Strong
3 Regular
5 Weak
Size
annual sales of £412.2k, make it smaller than the average company (£8.1m)
- Proton Therapy Usa Limited
£8.1m - Industry AVG
Growth
There is insufficient data available for this Key Performance Indicator!
- Proton Therapy Usa Limited
- - Industry AVG
Production
with a gross margin of 26.3%, this company has a comparable cost of product (26.3%)
- Proton Therapy Usa Limited
26.3% - Industry AVG
Profitability
an operating margin of 18.6% make it more profitable than the average company (0.6%)
- Proton Therapy Usa Limited
0.6% - Industry AVG
Employees
with 2 employees, this is below the industry average (64)
2 - Proton Therapy Usa Limited
64 - Industry AVG
Pay Structure
on an average salary of £56.9k, the company has an equivalent pay structure (£56.9k)
- Proton Therapy Usa Limited
£56.9k - Industry AVG
Efficiency
resulting in sales per employee of £206.1k, this is equally as efficient (£199.2k)
- Proton Therapy Usa Limited
£199.2k - Industry AVG
Debtor Days
it gets paid by customers after 66 days, this is later than average (52 days)
- Proton Therapy Usa Limited
52 days - Industry AVG
Creditor Days
its suppliers are paid after 21 days, this is quicker than average (26 days)
- Proton Therapy Usa Limited
26 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- Proton Therapy Usa Limited
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 0 weeks, this is less cash available to meet short term requirements (28 weeks)
0 weeks - Proton Therapy Usa Limited
28 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 24%, this is a lower level of debt than the average (47.7%)
24% - Proton Therapy Usa Limited
47.7% - Industry AVG
PROTON THERAPY USA LIMITED financials
Proton Therapy Usa Limited's latest turnover from June 2023 is estimated at £412.2 thousand and the company has net assets of £57.4 thousand. According to their latest financial statements, Proton Therapy Usa Limited has 2 employees and maintains cash reserves of £1 as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 | Jun 2016 | Jun 2015 | Jun 2014 | Jun 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | |||||||||||
| Other Income Or Grants | |||||||||||
| Cost Of Sales | |||||||||||
| Gross Profit | |||||||||||
| Admin Expenses | |||||||||||
| Operating Profit | |||||||||||
| Interest Payable | |||||||||||
| Interest Receivable | |||||||||||
| Pre-Tax Profit | |||||||||||
| Tax | |||||||||||
| Profit After Tax | |||||||||||
| Dividends Paid | |||||||||||
| Retained Profit | |||||||||||
| Employee Costs | |||||||||||
| Number Of Employees | 2 | ||||||||||
| EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 | Jun 2016 | Jun 2015 | Jun 2014 | Jun 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments & Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock & work in progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Debtors | 75,460 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Misc Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| misc current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total current assets | 75,461 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| total assets | 75,461 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 18,090 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total current liabilities | 18,090 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total liabilities | 18,090 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| net assets | 57,371 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| total shareholders funds | 57,371 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 | Jun 2016 | Jun 2015 | Jun 2014 | Jun 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||
| Operating Profit | |||||||||||
| Depreciation | 0 | 0 | 0 | 0 | 0 | ||||||
| Amortisation | 0 | 0 | 0 | 0 | 0 | ||||||
| Tax | |||||||||||
| Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors | 75,460 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creditors | 18,090 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Taxes & Provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash flow from operations | |||||||||||
| Investing Activities | |||||||||||
| capital expenditure | |||||||||||
| Change in Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| cash flow from investments | |||||||||||
| Financing Activities | |||||||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long term loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| share issue | |||||||||||
| interest | |||||||||||
| cash flow from financing | |||||||||||
| cash and cash equivalents | |||||||||||
| cash | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| change in cash | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
proton therapy usa limited Credit Report and Business Information
Proton Therapy Usa Limited Competitor Analysis
Perform a competitor analysis for proton therapy usa limited by selecting its closest rivals and benchmarking them against 12 key performance metrics.
proton therapy usa limited Ownership
PROTON THERAPY USA LIMITED group structure
Proton Therapy Usa Limited has no subsidiary companies.
proton therapy usa limited directors
Proton Therapy Usa Limited currently has 2 directors. The longest serving directors include Mr Jonathan Sinclair (Feb 2012) and Dr Michael Sinclair (Feb 2012).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Jonathan Sinclair | England | 49 years | Feb 2012 | - | Director |
| Dr Michael Sinclair | 81 years | Feb 2012 | - | Director |
P&L
June 2023turnover
412.2k
0%
operating profit
76.5k
0%
gross margin
26.4%
0%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
June 2023net assets
57.4k
+57370%
total assets
75.5k
+75460%
cash
1
0%
net assets
Total assets minus all liabilities
Similar Companies
proton therapy usa limited company details
company number
07964052
Type
Private limited with Share Capital
industry
26600 - Manufacture of irradiation, electromedical and electrotherapeutic equipment
incorporation date
February 2012
age
12
accounts
Total Exemption Full
ultimate parent company
previous names
N/A
incorporated
UK
address
flat 1 55 portland place, london, W1B 1QL
last accounts submitted
June 2023
proton therapy usa limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to proton therapy usa limited.
proton therapy usa limited Companies House Filings - See Documents
| date | description | view/download |
|---|
